alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
First Amendment to Amended and Restated Executive Employment Agreement



 Exhibit 10.2 
 FIRST AMENDMENT TO AMENDED AND RESTATED 
 EXECUTIVE EMPLOYMENT
AGREEMENT 
 This FIRST AMENDMENT TO THE AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT dated May 1, 2010 (the
“First Amendment”) is made as of January 25, 2012 between ARIAD Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and Maria E. Cantor (the “Employee”). 

WHEREAS, the Company and the Employee previously entered into an Amended and Restated Executive Employment Agreement dated May 1,
2010 (the “Agreement”), and the parties hereto desire further to amend certain provisions of the Agreement. 
 NOW,
THEREFORE, in consideration of the promises set forth herein and for other good and valuable consideration, the receipt of which is hereby acknowledged, the parties hereto agree further to amend the Agreement as follows: 

I. Severance – Section 6.2: 
 The entirety of Section 6.2 shall be replaced with the following: 
 “6.2
In the event of a consummation of a Change in Control of the Company, and if, upon such occurrence or within the period of one year following such occurrence, the Company terminates the Employee’s employment without Cause or the Employee
resigns for “Good Reason” (as defined herein), then, subject to compliance with Section 10 below, (i) all stock awards, stock options, restricted stock or restricted stock units granted to the Employee and past bonuses in the
form of deferred compensation granted to the Employee shall immediately vest and remain fully exercisable through their original term with all rights; (ii) the Company shall continue to pay the Employee his then-current base salary for
twenty-four (24) months; and (iii) if the Employee makes an effective COBRA election regarding group health insurance, then the Company shall continue to provide the Employee with coverage under the Company’s group health plan at the
Company’s expense for a period of 







 
eighteen months following Employee’s separation from the Company. Except as otherwise required under Section 14.2, salary continuation payments referenced in Section 6.2(ii) above
shall begin on the first regular pay date following Employee’s separation from service. Finally, the payments and benefits described in this Section 6.2 shall not be available if Employee’s employment terminates due to death or
disability during the one-year period following a Change of Control. 
 II. Except as modified by this First Amendment, the
Agreement remains in full force and effect. 
  

			
	ARIAD PHARMACEUTICALS, INC.,
		
	By:	 	 /s/ Harvey J. Berger, M.D.

		 	Harvey J. Berger, M.D.
		 	Chairman and Chief Executive Officer
	
	EMPLOYEE,
		
		 	 /s/ Maria E. Cantor

		 	Maria E. Cantor


 DATED: January 25, 2012 

  
 2
<PAGE>

                                                                    Exhibit 32.1

                           CERTIFICATIONS PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

     In connection with the Quarterly Report of Chromcraft Revington, Inc. (the
"Company") on Form 10-Q for the period ended July 1, 2006 as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), the
undersigned, Benjamin M. Anderson-Ray, Chairman and Chief Executive Officer, and
Frank T. Kane, Vice President - Finance and Chief Financial Officer of the
Company, hereby certify, to such officer's knowledge, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that:

     1.   The Report fully complies with the requirements of section 13(a) or
          15(d) of the Securities Exchange Act of 1934; and

     2.   The information contained in the Report fairly presents, in all
          material respects, the financial condition and results of operation of
          the Company.


/s/ Benjamin M. Anderson-Ray
-------------------------------------
Benjamin M. Anderson-Ray
Chairman and Chief Executive Officer
August 4, 2006



/s/ Frank T. Kane
-------------------------------------
Frank T. Kane
Vice President-Finance and
Chief Financial Officer
August 4, 2006
#### UNITED STATES of America, Plaintiff-Appellee, v. Humberto Chavez MORALES, a/k/a Mario Romero Vera, a/k/a Gallo, Defendant-Appellant.

No. 16-7769

United States Court of Appeals, Fourth Circuit.

Submitted: April 25, 2017

Decided: April 28, 2017

Humberto Chavez Morales, Appellant Pro Se.

Angela Hewlett Miller, Assistant United States Attorney, Greensboro, North Carolina, for Appellee.

Before MOTZ, DUNCAN, and AGEE, Circuit Judges.

Dismissed and remanded by unpublished per curiam opinion.

Unpublished opinions are not binding precedent in this circuit.

PER CURIAM:

Humberto Chavez Morales seeks to appeal the district court’s order adopting the magistrate judge’s recommendation and dismissing without prejudice his post-judgment motion. This court may exercise jurisdiction only over final orders, 28 U.S.C. § 1291 (2012), and certain interlocutory and collateral orders, 28 U.S.C. § 1292 (2012); Fed. R. Civ. P. 54(b); *Cohen v. Beneficial Indus. Loan Corp.,*337 U.S. 541, 545-47, 69 S.Ct. 1221, 93 L.Ed. 1528 (1949). Because the deficiencies identified by the district court may be remedied by filing a proper action in the correct district and using the correct forms, we conclude that the order Morales seeks to appeal is neither a final order nor an appealable interlocutory or collateral order. *See Domino Sugar Corp. v. Sugar Workers Local Union 392,*10 F.3d 1064, 1066-67 (4th Cir. 1993). Accordingly, we dismiss Morales’ appeal for lack of jurisdiction and remand the case to the district court with instructions to allow Morales to amend. *See Goode v. Cent. Va. Legal Aid Soc’y, Inc.,*807 F.3d 619, 623-24 (4th Cir. 2015). We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before this *280court and argument would not aid the decisional process.

*DISMISSED & REMANDED*
Exhibit 10.2


 


SECURED
TERM PROMISSORY NOTE


 


	$750,000	Advance Date:     February
27, 2019
	 	 
	 	Maturity Date:  September 30, 2019


 


FOR
VALUE RECEIVED, Ondas Holdings Inc., a Nevada corporation, for itself and each of its Subsidiaries (the “Borrower”)
hereby promises to pay to the order of Energy Capital, LLC, a Florida limited liability company, or the holder of this Note (the
“Lender”) at Lender's address listed in Loan Agreement, or such other place of payment as the holder of this Secured
Term Promissory Note (this “Promissory Note”) may specify from time to time in writing, in lawful money of the United
States of America, the principal amount of Seven Hundred Fifty Thousand Dollars ($750,000) or such lesser principal amount as
Lender has advanced to Borrower, together with interest as set forth in that certain Loan and Security Agreement dated October
1, 2018, by and among Borrower, its Domestic Subsidiaries party thereto and Lender (as the same may from time to time be amended,
modified or supplemented in accordance with its terms, the “Loan Agreement”).


 


This
Promissory Note is the Term Note referred to in, and is executed and delivered in connection with, the Loan Agreement, and is
entitled to the benefit and security of the Loan Agreement and the other Loan Documents (as defined in the Loan Agreement), to
which reference is made for a statement of all of the terms and conditions thereof. All payments shall be made in accordance with
the Loan Agreement. All terms defined in the Loan Agreement shall have the same definitions when used herein, unless otherwise
defined herein. An Event of Default under the Loan Agreement shall constitute an Event of Default under this Promissory Note.


 


Borrower
waives presentment and demand for payment, notice of dishonor, protest and notice of protest under the UCC or any applicable law.
Borrower agrees to make all payments under this Promissory Note without setoff, recoupment or deduction and regardless of any
counterclaim or defense. This Promissory Note has been negotiated and delivered to Lender and is payable in the State of Florida.
This Promissory Note shall be governed by and construed and enforced in accordance with, the laws of the State of Florida, excluding
any conflicts of law rules or principles that would cause the application of the laws of any other jurisdiction.


 


BORROWER
FOR ITSELF AND ON BEHALF OF ITS SUBSIDIARIES: 


 


	 	ONDAS HOLDINGS INC.
	 	 	 
	 	By:	/s/ Eric A. Brock
	 	 	Eric A. Brock, Chief Executive Officer
I 

118TH CONGRESS 

1ST SESSION H. R. 624 

To amend the Victims of Crime Act of 1984 to authorize compensation 

for victims of illicit fentanyl poisoning, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

JANUARY 30, 2023 

Mr. CARTER of Georgia introduced the following bill; which was referred to 

the Committee on the Judiciary 

A BILL 

To amend the Victims of Crime Act of 1984 to authorize 

compensation for victims of illicit fentanyl poisoning, and 

for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Recognizing Victims 

5 of Illicit Fentanyl Poisoning Act’’. 

6 SEC. 2. RECOGNIZING VICTIMS OF ILLICIT FENTANYL POI7 SONING. 

8 Section 1403(d) of the Victims of Crime Act of 1984 

9 (34 U.S.C. 20102) is amended— 


kjohnson on DSK79L0C42PROD with BILLS
2 

•HR 624 IH

1 (1) in paragraph (3), by striking ‘‘and domestic 

2 violence’’ and inserting ‘‘domestic violence, and illicit 

3 fentanyl poisoning resulting in death’’; 

4 (2) in paragraph (4), by striking ‘‘and’’ at the 

5 end; 

6 (3) in paragraph (5), by striking the period and 

7 inserting ‘‘; and’’; and 

8 (4) by adding at the end the following: 

9 ‘‘(6) the term ‘illicit fentanyl’ means fentanyl 

10 and any analogue thereof that is manufactured, dis11 tributed, or dispensed, or possessed with intent to 

12 manufacture, distribute, or dispense, in violation of 

13 section 401, 406, or 416 of the Controlled Sub14 stances Act.’’. 

Æ 


kjohnson on DSK79L0C42PROD with BILLS
**EXHIBIT      32.1**

**CERTIFICATION      PURSUANT TO **

**SECTION      906 OF THE SARBANES-OXLEY ACT OF 2002**

| 1.   | The              Report fully complies with the requirements of Section 13(a) or 15(d)              of              the Securities Exchange Act of 1934; and |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.   | The              information contained in the Report fairly presents, in all material              respects, the financial condition and result of operations of the              Company. |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| By:    | /s/                Mark R. Newburg                                                                                          | Dated:December                9, 2005 |
|--------|-----------------------------------------------------------------------------------------------------------------------------|---------------------------------------|
|   | Mark                R. Newburg                                                                                              |                                  |
| Title: | President,                Chief Executive Officer                and Treasurer (Principal                Executive Officer) |                                  |
|   |                                                                                                                        |                                  |
| By:    | /s/                Arnaldo F. Galassi                                                                                       | Dated:December                9, 2005 |
|   | Arnaldo                F. Galassi                                                                                           |                                  |
| Title: | Chief                Financial Officer and Secretary (Principal Financial                Officer)                           |                                  |

----
##### 



EXHIBIT 32.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The undersigned, Gerald E. Bisbee, Jr. the Chief Executive Officer of
ReGen Biologics, Inc. (the Company), has executed this certification in
connection with the filing with the Securities and Exchange Commission of the
Companys Quarterly Report on Form 10-Q for the quarterly period ending March
31, 2004 (the Report). The undersigned hereby certifies that: (1) the Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and (2) the information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company. Date: May 14, 2004
    
    /s/ Gerald E. Bisbee, JrName: Gerald E. Bisbee, JrTitle: Chief Executive Officer
Curtis Ray MCCARTY, Jr. v. Arthur WOOD, III

2016-CT-00928-SCT

Supreme Court of Mississippi.

Filed: May 29, 2018 Closed: May 30, 2018

No Action Taken
<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                          31,625
<SECURITIES>                                         0
<RECEIVABLES>                                3,324,533
<ALLOWANCES>                                    20,000
<INVENTORY>                                  5,068,861
<CURRENT-ASSETS>                             8,798,872
<PP&E>                                       2,060,662
<DEPRECIATION>                               1,050,194
<TOTAL-ASSETS>                               9,827,452
<CURRENT-LIABILITIES>                        6,023,521
<BONDS>                                              0
<PREFERRED-MANDATORY>                        1,966,513
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                 9,827,452
<SALES>                                     18,037,031
<TOTAL-REVENUES>                            18,037,031
<CGS>                                       13,394,219
<TOTAL-COSTS>                               13,394,219
<OTHER-EXPENSES>                             3,163,302
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             150,863
<INCOME-PRETAX>                              1,328,647
<INCOME-TAX>                                   518,000
<INCOME-CONTINUING>                            810,647
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   810,647
<EPS-BASIC>                                       0.16
<EPS-DILUTED>                                     0.14


</TABLE>
[Federal Register Volume 87, Number 33 (Thursday, February 17, 2022)]
[Notices]
[Page 9057]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-03420]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2019-N-0895]


Issuance of Priority Review Voucher; Material Threat Medical 
Countermeasure Product

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the 
issuance of a priority review voucher to the sponsor of a material 
threat medical countermeasure (MCM) product application. The Federal 
Food, Drug, and Cosmetic Act (FD&C Act), as amended by the 21st Century 
Cures Act (Cures Act), authorizes FDA to award priority review vouchers 
to sponsors of approved material threat MCM product applications that 
meet certain criteria. FDA is required to publish notice of the award 
of the priority review voucher. FDA has determined that SPIKEVAX 
(COVID-19 Vaccine, mRNA), meets the criteria for a material threat 
priority review voucher, which has been issued to ModernaTX, Inc., the 
holder of the biologics license application.

FOR FURTHER INFORMATION CONTACT: Myrna Hanna, Center for Biologics 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240-
402-7911.

SUPPLEMENTARY INFORMATION: FDA is announcing the issuance of a material 
threat MCM priority review voucher to the sponsor of an approved 
material threat MCM product application. Under section 565A of the FD&C 
Act (21 U.S.C. 360bbb-4a), which was added by the Cures Act (Pub. L. 
114-255), FDA will award priority review vouchers to sponsors of 
approved material threat MCM product applications that meet certain 
criteria upon approval of those applications. FDA has determined that 
SPIKEVAX (COVID-19 Vaccine, mRNA), meets the criteria for a material 
threat MCM priority review voucher. SPIKEVAX is indicated for active 
immunization to prevent coronavirus disease 2019 (COVID-19) caused by 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 
individuals 18 years of age and older.
    For further information about the material threat MCM Priority 
Review Voucher Program and for a link to the full text of section 565A 
of the FD&C Act, go to https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/mcm-related-counterterrorism-legislation. For further information about SPIKEVAX, 
(COVID-19 Vaccine, mRNA), go to the Center for Biologics Evaluation and 
Research Approved Vaccine Products website at https://www.fda.gov/vaccines-blood-biologics/vaccines/approved-vaccine-products.

    Dated: February 11, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-03420 Filed 2-16-22; 8:45 am]
BILLING CODE 4164-01-P
Kristen L. BELLANT, Appellant, v. George M. BELLANT, Appellee.

Case No. 2D17-2013

District Court of Appeal of Florida, Second District.

Opinion filed March 16, 2018

**DECISION WITHOUT PUBLISHED OPINION**

Affirmed.
Opinion issued June 5, 2014

In The

Court of Appeals 

For The 

First District of Texas 

————————————

NO. 01-14-00321-CR

———————————

RONALD WAYNE SCHOFIELD, Appellant

V.

THE STATE OF TEXAS, Appellee

On Appeal from the 239th District Court

Brazoria County, Texas

Trial Court Case Nos. 34910 (Counts I & II)

MEMORANDUM OPINION

Appellant, Ronald Wayne Schofield, attempts to appeal from an order of the

trial court denying his motion for judgment nunc pro tunc. The denial of a motion 

for judgment nunc pro tunc is not an appealable order. See Lozano v. State, No. 

01-13-00180-CR, 2013 WL 2106570, at *1 (Tex. App.—Houston [1st Dist.] May 
2

14, 2013, no pet.) (mem. op., not designated for publication); Zelaya v. State, Nos. 

01-11-00977-CR, 01-11-00978-CR, 01-11-00979-CR, 2013 WL 127439, at *1 

(Tex. App.—Houston [1st Dist.] Jan. 10, 2013, no pet.) (mem. op., not designated 

for publication); Everett v. State, 82 S.W.3d 735, 735 (Tex. App.—Waco 2002, 

pet. dism’d); see also Ex parte Florence, 319 S.W.3d 695, 696 (Tex. Crim. App. 

2010) (“If the trial court denies the motion for judgment nunc pro tunc or fails to 

respond, relief may be sought by filing an application for writ of mandamus in a 

court of appeals.”). 

Accordingly, we dismiss the appeal for want of jurisdiction. We dismiss all 

pending motions as moot.

PER CURIAM

Panel consists of Chief Justice Radack and Justices Higley and Brown.

Do not publish. TEX. R. APP. P. 47.2(b).
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### National Science Foundation

The National Science Board's Committee on Awards & Facilities hereby gives notice of the scheduling of a teleconference for the transaction of National Science Board business pursuant to the National Science Foundation Act and the Government in the Sunshine Act.

# TIME AND DATE: 

Tuesday, February 22, 2022, from 1:00-1:45 p.m. EST.

# PLACE: 

This meeting will be held by teleconference through the National Science Foundation.

# STATUS: 

Open.

# MATTERS TO BE CONSIDERED: 

The agenda of the teleconference is: Committee Chair's opening remarks; approval of prior meeting minutes; schedule of context and action items; and Information Item: Antarctic research vessel design stage briefing.

# CONTACT PERSON FOR MORE INFORMATION: 

                        Point of contact for this meeting is: Chris Blair,                         *cblair@nsf.gov,*                         703/292-7000. The You Tube link to watch this meeting live is:                         *https://youtu.be/​rMKInQzCQ28.*                         Meeting updates may be found at the National Science Board website                         *www.nsf.gov/​nsb.*

Chris Blair,

Executive Assistant to the National Science Board Office.

[FR Doc. 2022-03639 Filed 2-16-22; 11:15 am]

BILLING CODE 7555-01-P
M.G. v. CALHOUN COUNTY DEPARTMENT OF HUMAN RESOURCES

2160213

Court of Civil Appeals of Alabama.

June 9, 2017

**DECISION WITHOUT PUBLISHED OPINION**

Affirmed.